New Vice Chair named for NRG Health Disparities Committee
October 24, 2023
Evan M. Graboyes, MD, MPH, is an Associate Professor in the Departments of Otolaryngology-Head & Neck Surgery and Public Health Sciences at the Medical University of South Carolina (MUSC) where he is the Director of Survivorship and Cancer Outcomes Research (SCOR) at the NCI-designated Hollings Cancer Center. He is an active member of the HDC, Co-Chairing the HDC’s Research Concept Development Special Interest Group with outgoing HDC Vice Chair, Chanita Hughes-Halbert since 2022.
Dr. Graboyes has dedicated his professional career as a cancer surgeon and health services researcher to understanding and addressing issues related to cancer disparities, cancer care delivery, and health-related social risks among patients with cancer along the treatment continuum. He has led multiple NCI-funded randomized clinical trials and foundation awards evaluating supportive care and equity-focused health services interventions in patients with cancer. In addition to his service with NRG Oncology, Dr. Graboyes is an active contributor to cancer disparities, cancer care delivery, and survivorship research and initiatives at the National Cancer Institute, the American Society of Clinical Oncology, the American Head and Neck Society, and the Commission on Cancer.
Dr. Graboyes’s appointment as Vice Chair of the NRG Oncology’s Health Disparities Committee will enhance NRG Oncology’s capacity to incorporate health disparities research within NRG clinical trials through concept development and resulting protocols, as well as the creation of ancillary studies.Through this new appointment he will also help to expand the HDC health disparities educational and mentoring efforts through the NRG NCORP and NCTN programs.
We are delighted to officially welcome Dr. Graboyes in his new role as Vice-Chair, recognizing his ongoing commitment to the HDC and to NRG Oncology as well as the many contributions of his NRG Mentor, Dr. Chanita Hughes-Halbert.
Related Posts
Combo Extends OS in Patients 65+ with Ph+ ALL
Long-term results show combination treatment that skips chemotherapy is effective for older patients with Ph+ ALL
Model Predicts AI Non-adherence Risk
A new risk model uses baseline sociodemographic and financial measures to predict which patients prescribed long-term therapy with aromatase inhibitors for breast cancer are at significantly higher risk of stopping that therapy early
ECOG-ACRIN and PrECOG announce multiple presentations at ASH 2023
Researchers with the ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present six oral and three poster presentations at the 65th American Society of Hematology Meeting & Exposition